172 related articles for article (PubMed ID: 33135102)
21. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
22. The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.
Perdrizet K; Leighl NB
Curr Treat Options Oncol; 2019 Feb; 20(3):21. PubMed ID: 30778772
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab-based therapy for advanced small bowel adenocarcinoma.
Tsang H; Yau T; Khong PL; Epstein RJ
Gut; 2008 Nov; 57(11):1631-2. PubMed ID: 18941013
[No Abstract] [Full Text] [Related]
24. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater.
Gulhati P; Raghav K; Shroff R; Varadhachary G; Javle M; Qiao W; Wang H; Morris J; Wolff R; Overman MJ
Oncologist; 2018 Mar; 23(3):277-e26. PubMed ID: 29259073
[TBL] [Abstract][Full Text] [Related]
25. Current and advancing treatments for metastatic colorectal cancer.
Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapy in colorectal cancer: current status and future challenges.
Koutras AK; Starakis I; Kyriakopoulou U; Katsaounis P; Nikolakopoulos A; Kalofonos HP
Curr Med Chem; 2011; 18(11):1599-612. PubMed ID: 21428886
[TBL] [Abstract][Full Text] [Related]
27. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.
Press MF; Lenz HJ
Drugs; 2007; 67(14):2045-75. PubMed ID: 17883287
[TBL] [Abstract][Full Text] [Related]
28. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
29. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.
Wang G; He Y; Sun Y; Wang W; Qian X; Yu X; Pan Y
Clin Transl Oncol; 2020 Jun; 22(6):813-822. PubMed ID: 31587152
[TBL] [Abstract][Full Text] [Related]
30. [Targeted therapy in locally and metastatic recurrent cervical cancers].
Geiss R; De La Motte Rouge T; Dubot C; Leary A; Lhommé C; Pautier P; Scholl S; Rodrigues MJ
Bull Cancer; 2014; 101(7-8):748-55. PubMed ID: 25091657
[TBL] [Abstract][Full Text] [Related]
31. Management of small bowel adenocarcinoma.
Kummar S; Ciesielski TE; Fogarasi MC
Oncology (Williston Park); 2002 Oct; 16(10):1364-9; discussion 1370, 1372-3. PubMed ID: 12435206
[TBL] [Abstract][Full Text] [Related]
32. A heavily pre-treated adenocarcinoma patient with EGFR exon 20 insertion mutation responded to pembrolizumab plus nab-paclitaxel/bevacizumab: a case report.
Huang X; Yang Y; Wang P; Han-Zhang H; Ding L
Ann Palliat Med; 2021 Jun; 10(6):6997-7002. PubMed ID: 33183015
[TBL] [Abstract][Full Text] [Related]
33. Molecularly targeted therapy for gastrointestinal cancer.
Wiedmann MW; Caca K
Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
[TBL] [Abstract][Full Text] [Related]
34. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.
Laforest A; Aparicio T; Zaanan A; Silva FP; Didelot A; Desbeaux A; Le Corre D; Benhaim L; Pallier K; Aust D; Pistorius S; Blons H; Svrcek M; Laurent-Puig P
Eur J Cancer; 2014 Jul; 50(10):1740-1746. PubMed ID: 24797764
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapy for advanced esophagogastric adenocarcinoma.
Kordes S; Cats A; Meijer SL; van Laarhoven HW
Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
[TBL] [Abstract][Full Text] [Related]
36. [A perspective: role of targeted therapy in colon cancer].
Chung HH; Jang BI
Korean J Gastroenterol; 2013 Mar; 61(3):128-35. PubMed ID: 23575231
[TBL] [Abstract][Full Text] [Related]
37. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
Daum O; Skálová A; Rozkos T; Laco J
Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
[TBL] [Abstract][Full Text] [Related]
38. Colorectal Cancer: Why Does Side Matter?
Gallois C; Pernot S; Zaanan A; Taieb J
Drugs; 2018 Jun; 78(8):789-798. PubMed ID: 29790124
[TBL] [Abstract][Full Text] [Related]
39. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
[TBL] [Abstract][Full Text] [Related]
40. Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.
Chebib R; Verlingue L; Cozic N; Faron M; Burtin P; Boige V; Hollebecque A; Malka D
Semin Oncol; 2017 Apr; 44(2):114-128. PubMed ID: 28923209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]